Latest Security News

Rhythm Biosciences has begun commercialising its blood-based colorectal cancer test, ColoSTAT®, following key accreditations and validation. The company also secured a strategic partnership with NHS England and expanded its geneType™ platform globally.

Anteris Technologies has closed a $320 million capital raise, combining a $230 million public offering and a strategic private placement with Medtronic, to advance its DurAVR heart valve clinical trials and manufacturing growth.

Celsius Resources has released a Definitive Feasibility Study for its Maalinao-Caigutan-Biyog (MCB) Copper-Gold Project, confirming robust economics and a 35-year mine life. The study highlights strong returns, low operating costs, and a clear path to development in the Philippines.

Accelerate Resources has advanced its gold exploration at Balagundi and manganese prospects in Pilbara, bolstered by a $900,000 capital raise and a strategic joint venture at the Comet Gold Project.

Anteris Technologies Global Corp. has entered a material definitive agreement to raise approximately $320 million through a public offering and a strategic private placement with Medtronic’s subsidiary. The capital will support clinical trials and manufacturing expansion for its innovative heart valve technology.

EPX Limited has successfully raised nearly $295,000 through a Security Purchase Plan, supporting its recent acquisition of Wattwatchers and positioning the company for further expansion.

DMC Mining Limited will be delisted from the ASX on 27 January 2026 following a two-year suspension, but the company remains committed to relisting pending key exploration licences in Guinea.

Cambium Bio has strengthened its financial footing with a $0.6 million R&D tax refund and a $2.4 million strategic placement, setting the stage for pivotal Phase 3 clinical trials of its lead ophthalmology candidate.

Ballard Mining has raised $61 million through a well-supported placement to fund an aggressive drilling program and early development works at its Mt Ida Gold Project, positioning the company for a Final Investment Decision.

Guzman y Gomez has secured a multi-year exclusive delivery partnership with Uber Eats in Australia, aiming to accelerate growth and enhance customer convenience. Delivery now accounts for over a quarter of GYG’s Australian sales, underscoring its strategic importance.

Nyrada Inc. has secured ethics approval to launch a Phase IIa clinical trial for its heart attack drug Xolatryp®, with patient recruitment set for March 2026. The company maintains a solid cash position of AU$7.12 million as it expands its research into oncology.

Arovella Therapeutics has filed an IND application for its lead CAR-iNKT therapy ALA-101, selected a CRO for its upcoming phase 1 trial, and secured $19.4 million in cash to fund clinical progress and pipeline expansion.